Hunan Jingfeng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
April 29, 2020 at 12:47 pm EDT
Share
Hunan Jingfeng Pharmaceutical Co.,Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was CNY 1,344.029 million compared to CNY 2,585.696 million a year ago. Operating loss was CNY 908.394 million compared to operating Income of CNY 254.934 million a year ago. Net loss was CNY 882.806 million compared to net income of CNY 186.812 million a year ago. Basic loss per share from continuing operations was CNY 1.0034 compared to basic earnings per share from continuing operations of CNY 0.2123 a year ago.
Hunan Jingfeng Pharmaceutical Co.,Ltd., formerly Hunan Tianyi Science and Technology Co., Ltd, is a China-based company principally engaged in the research, development, manufacture and sale of chemical drugs, biochemical drugs and traditional Chinese patent drugs. The Company's main products includes cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs and anti-infective drugs, among others. The Company is also involved in commodity import and export trading, business management and consulting, as well as medical technology consulting business. The Company distributes its products in the domestic market.
HUNAN JINGFENG PHARMACEUTICAL CO.,LTD. 
